Search

Corvus Pharmaceuticals Inc

Geschlossen

14.06 -5.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.91

Max

15.17

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.4M

-14M

EPS

-0.15

Angestellte

37

EBITDA

312K

-12M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+112.08% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-29M

1.3B

Vorheriger Eröffnungskurs

19.76

Vorheriger Schlusskurs

14.06

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Juli 2026, 23:51 UTC

Bitcoin dips amid crypto volatility, while Ethereum rises; South Korea's GDP trends and geopolitical tensions raise concerns for regional market stability.

19. Juli 2026, 23:51 UTC

"Bitcoin dips as Ethereum rises amid geopolitical tensions and South Korea's GDP data, with key economic indicators on the horizon."

19. Juli 2026, 23:51 UTC

"Bitcoin Declines Amid Mixed Crypto Performance; South Korea's GDP and ASEAN Interest Rate Talks Signal Potential Market Shifts."

19. Juli 2026, 23:51 UTC

Mixed cryptocurrency performance amid geopolitical tensions and economic uncertainties, with South Korea's GDP figures and rising U.S. margin debt raising investor concerns.

19. Juli 2026, 23:51 UTC

Bitcoin is trading lower today, continuing a trend following Friday's declines in U.S. equity markets. It remains above its 20-day moving average.

19. Juli 2026, 23:41 UTC

Canada's New Housing Price Index set for July 24, with a forecasted decline of -0.2% amid cautious market sentiment and ongoing economic pressures.

19. Juli 2026, 23:21 UTC

Upcoming Chicago Fed National Activity Index release on July 23, 2026, may signal U.S. economic growth amidst mixed sentiment and inflation concerns.

19. Juli 2026, 23:21 UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.4% in May Amid Cautious Optimism on Consumer Spending

19. Juli 2026, 23:11 UTC

Correlated Moves

During after-market hours, SGD/CHF is higher, reflecting a slight gain since Friday's close. The asset exhibited notable volatility amid broader macroeconomic trends.

19. Juli 2026, 23:11 UTC

ECB Expected to Maintain Interest Rate at 2.4% Amid Rising Energy Costs and Global Economic Concerns

19. Juli 2026, 23:11 UTC

Euro Area's Deposit Facility Rate Expected to Hold Steady at 0.0225% Amid Cautious Market Sentiment and Geopolitical Tensions

19. Juli 2026, 23:01 UTC

China's Loan Prime Rate Expected to Hold Steady at 3.50% Amid Cautious Economic Sentiment and Geopolitical Tensions Ahead of July Release

19. Juli 2026, 23:01 UTC

China's Loan Prime Rate (LPR) 1Y release on July 20, 2026, forecasted at a cautious 0.03%, amid economic concerns impacting consumer spending and credit demand.

19. Juli 2026, 23:01 UTC

After-market trading for GBP/ZAR shows gains since Friday's close, fluctuating throughout the session and remaining near the upper end of its one-month range.

19. Juli 2026, 23:01 UTC

Macro News
Correlated Moves

GBP/USD declines in after-hours trading as the U.S. dollar strengthens against major currencies, reflecting broader investor sentiment and geopolitical tensions.

19. Juli 2026, 23:01 UTC

GBP/CHF is higher in after-market trading, reaching the upper end of its one-month trading range despite no specific news identified for today's move.

19. Juli 2026, 22:51 UTC

USD/NOK is trading higher in after-market hours, moving from a low to a high since Friday's close, despite remaining below its 20-day moving average.

19. Juli 2026, 22:31 UTC

Japan's Inflation Rate Release on July 23, 2026: Market Eyes Potential Impact of Recent Economic Shifts and Extreme Weather on Monetary Policy.

19. Juli 2026, 22:31 UTC

Japan's Core Inflation Rate Expected to Rise to 1.6% Amid Economic Concerns and Geopolitical Tensions Ahead of July Release

19. Juli 2026, 22:21 UTC

GBP/NOK is higher in after-hours trading, reaching the upper end of its one-month range. No specific news was identified for this price move.

19. Juli 2026, 22:21 UTC

EUR/SEK advanced in after-market trading, reaching a peak above previous levels. The performance contrasts with its position in the one-month trading range.

19. Juli 2026, 22:21 UTC

Mortgage Rates Hit Nine-Month High at 6.65%, Raising Concerns Over Housing Affordability and Consumer Spending Ahead of Upcoming MBA Data Release

19. Juli 2026, 22:21 UTC

Canada's June 2026 Inflation Rate Release Sparks Caution Amid Rising Gas Prices and Mixed Market Expectations

19. Juli 2026, 22:21 UTC

Canada's Inflation Rate Expected to Decrease by 0.002% in June, Signaling Potential Deflationary Pressures Ahead of July Release

19. Juli 2026, 22:21 UTC

Canada's Core Inflation Rate Release on July 20, 2026 Expected to Impact Monetary Policy Amid Ongoing Economic Pressures.

19. Juli 2026, 22:21 UTC

Correlated Moves

Avalanche is declining during Sunday’s session, reflecting broader cryptocurrency market sentiment. The asset remains below its 20-day moving average.

19. Juli 2026, 22:11 UTC

Correlated Moves

Gold/CAD is declining in the ongoing session, continuing a downward trend since Friday's close, with Silver also showing weakness.

19. Juli 2026, 22:11 UTC

Correlated Moves

Gold Ounce vs Euro is trading lower, reflecting a decline since Friday's close, influenced by a drop in Silver prices and macroeconomic factors.

19. Juli 2026, 22:11 UTC

Correlated Moves

Gold/JPY is trading lower, continuing a decline since Friday's close. The asset remains below its 20-day moving average amid broader weakness in precious metals.

19. Juli 2026, 22:11 UTC

Macro News

Crude oil prices are rising amid concerns over shipping route disruptions and escalating U.S.-Iran tensions. Prices have regained momentum above the 20-day moving average.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

112.08% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD  112.08%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat